Vitrolife Group (VITR) Pre-close call presentation summary

Market and operational outlook

• North America IVF cycle volumes are normalizing, with growth expected to return to 2024 levels by mid-2026.

• Middle East IVF cycles remain below 2025 levels due to ongoing regional crisis, though operations are not disrupted.

• Strategic investments in US sales and marketing are complete; ongoing IT investments aim to boost efficiency and customer experience.

• Negative currency effects are anticipated to continue in Q1 2026.

• IVF cycle growth is projected to gradually recover, targeting mid single-digit growth in line with historical trends.

Genetic services restructuring

• Strategic review led to discontinuation of GPDX and NACE test lines by March 2026.

• Exit from low-profit markets will affect about 6% of the workforce, with full execution expected in three quarters.

• Discontinued business represents 2-3% of annual revenue.

• Annualized savings of SEK 65 million targeted, with main savings realized from Q2 2026.

• SEK 5.4 billion goodwill impairment related to Igenomix recognized in Q4 2025.

Strategic positioning and investment rationale

• Resilient underlying market growth and a high-quality portfolio support long-term objectives.

• Strong track record of profitable growth and leadership in fertility innovation and technology.

• Ambitious strategy underpins continued investment appeal.